Drs Ursula A. Matulonis and Akila N. Viswanathan discuss the role of radiation therapy in endometrial cancer, including staging, immunotherapy, and treatment disparities.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999853. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer Through Activation of Innate Immune Responses https://pubmed.ncbi.nlm.nih.gov/38169513/

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/16330675/

Adjuvant Chemotherapy Plus Radiation for Locally Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/31189035/

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone for Women With High-Risk Endometrial Cancer (PORTEC-3): Final Results of an International, Open-Label, Multicentre, Randomised, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/29449189/

Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/

FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/

Polymerase ɛ (POLE) Mutations in Endometrial Cancer: Clinical Outcomes and Implications for Lynch Syndrome Testing https://pubmed.ncbi.nlm.nih.gov/25224212/

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/37487144/

Risk Factors and Survival Impact Associated With Documentation of Radiation Therapy Refusal in Patients With Gynecologic Cancer https://pubmed.ncbi.nlm.nih.gov/37657506/

Drs Ursula A. Matulonis and Mansoor Mirza discuss immunotherapy trials, novel therapies such as CDK4/6 inhibitors and antibody-drug conjugates, and shared decision-making.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999852. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/

Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial https://pubmed.ncbi.nlm.nih.gov/37864337/

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) https://pubmed.ncbi.nlm.nih.gov/33078978/

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/37669480/

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/

Drs Ursula A. Matulonis and Bhavana Pothuri discuss solutions to address health disparities in the diagnosis and treatment of endometrial cancer.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999851. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Differential Trends in Rising Endometrial Cancer Incidence by Age, Race, and Ethnicity https://pubmed.ncbi.nlm.nih.gov/36625534/

Risk of Female-Specific Cancers According to Obesity and Menopausal Status in 2.7 Million Korean Women: Similar Trends Between Korean and Western Women https://pubmed.ncbi.nlm.nih.gov/34327357/

Uterine Cancer Is on the Rise, Especially Among Black Women https://www.nytimes.com/2022/06/17/health/uterine-cancer-black-women.html

New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines https://pubmed.ncbi.nlm.nih.gov/34073635/

A Molecular Perspective: Racial Disparities in Uterine Serous Carcinoma https://www.sciencedirect.com/science/article/abs/pii/S0090825822013105

Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy https://pubmed.ncbi.nlm.nih.gov/38529411/

Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/30741844/

Demographic Reporting and Language Exclusion in Gynecologic Oncology Clinical Trials https://pubmed.ncbi.nlm.nih.gov/37751830/

What's in It for Me?: A Value Assessment of Gynecologic Cancer Clinical Trials for Black Women https://pubmed.ncbi.nlm.nih.gov/36931101/

Just Ask! Increasing Diversity in Cancer Clinical Research https://courses.accc-cancer.org/products/just-ask-increasing-diversity-in-cancer-clinical-research#tab-product_tab_overview

Translational Research: Bridging the Gap Between Preclinical and Clinical Research https://pubmed.ncbi.nlm.nih.gov/36722550/

WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer Through Activation of Innate Immune Responses https://pubmed.ncbi.nlm.nih.gov/38169513/

ROCC/GOG-3043: A Randomized Non-inferiority Trial of Robotic Versus Open Radical Hysterectomy for Early-Stage Cervical Cancer https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS5605

Diverse Trials Act https://aaci-library.org/legislation-tracker/diverse-trials-act